POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular fluid volume, acid-base balance, and nerve impulse transmission. Dextrose provides caloric supplementation and sodium chloride maintains extracellular fluid volume and electrolyte balance. The combination corrects electrolyte and fluid deficits.
| Metabolism | Potassium chloride is not metabolized; potassium is excreted primarily by the kidneys. Dextrose is metabolized via glycolysis and the citric acid cycle. |
| Excretion | Renal: potassium >90% excreted in urine (glomerular filtration, distal tubular secretion); chloride 95% renally; dextrose nearly completely reabsorbed; sodium >99% renally with reabsorption. |
| Half-life | Potassium: 2-4 hours (plasma, no true terminal t½ due to rapid equilibration with intracellular stores); clinical context: half-life prolonged in renal impairment. |
| Protein binding | Potassium: 0% unbound; chloride: 0% unbound; dextrose: 0%; sodium: 0%. |
| Volume of Distribution | Potassium: 0.4-0.6 L/kg (total body water); clinical meaning: reflects distribution into intracellular fluid (98% body potassium is intracellular). |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: within minutes for potassium repletion (cardiac effects seen in seconds with ECG changes). |
| Duration of Action | Intravenous: 2-4 hours for electrolyte effects; duration depends on infusion rate and total dose; continuous infusion required for sustained repletion. |
| Molecular Weight | 74.55 (KCl), 180.16 (dextrose), 58.44 (NaCl) |
Intravenous infusion; dose depends on serum potassium levels and body weight. Typical adult maintenance: 10-20 mEq/hour, not exceeding 40 mEq/hour or 200 mEq/day. Concentration used: 0.3% potassium chloride (40 mEq/L) in D5 0.2% NaCl.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR <30 mL/min: Reduce dose by 50% and monitor serum potassium closely. Avoid if GFR <10 mL/min unless severe hypokalemia. For GFR 30-50 mL/min: Use with caution, reduce dose by 25%. |
| Liver impairment | No specific Child-Pugh based adjustments. However, in severe hepatic impairment (Child-Pugh C), use with caution due to risk of hyperkalemia and fluid overload; monitor potassium levels frequently. |
| Pediatric use | Weight-based: 0.2-0.5 mEq/kg/hour intravenously; maximum rate 0.5 mEq/kg/hour. For maintenance: 2-3 mEq/kg/day. Adjust based on serum potassium monitoring. |
| Geriatric use | Elderly patients may have reduced renal function; start at lower end of dosing (e.g., 10 mEq/hour) and titrate based on potassium levels and renal function. Monitor for fluid overload due to dextrose and sodium content. |
| 1st trimester | Potassium chloride and dextrose/sodium chloride solutions are generally considered safe in pregnancy when used for fluid and electrolyte maintenance or replacement. No teratogenicity in animal studies; use only if clearly needed. |
| 2nd trimester | Safe for maternal hydration and electrolyte balance; monitor serum potassium and glucose levels. |
| 3rd trimester | Safe for use during labor and delivery; caution in preeclampsia or impaired renal function due to risk of hyperkalemia. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium crosses the placenta by active transport; dextrose crosses freely; sodium and chloride cross readily. Fetal serum levels equilibrate with maternal levels. No evidence of harm at therapeutic doses. |
| Breastfeeding | Potassium chloride and dextrose/sodium chloride are normal constituents of breast milk and body fluids. Intravenous infusion does not pose a risk to the nursing infant. Monitor maternal electrolytes if high doses are used. |
| Lactation Rating | Safe |
| Teratogenic Risk | Potassium chloride, dextrose, and sodium chloride at these concentrations pose minimal fetal risk when used as maintenance fluids. No specific teratogenicity is associated with potassium chloride or 5% dextrose/0.2% sodium chloride. However, maternal hyperglycemia from dextrose may increase risk of neural tube defects and macrosomia in first trimester; fetal/neonatal hypoglycemia with excessive dextrose infusion. Potassium imbalance (hyper/hypokalemia) may affect fetal cardiac function. Generally considered safe when maternal electrolyte balance is maintained. |
| Fetal Monitoring | Monitor maternal serum potassium, sodium, glucose, renal function, and fluid status. Fetal monitoring indicated for signs of electrolyte imbalance or fluid overload (e.g., nonstress test or biophysical profile in high-risk pregnancies). Assess for maternal edema, hypertension, or signs of hyper/hypokalemia (ECG changes). |
| Fertility Effects | No known effects on fertility or reproductive function. Potassium chloride, dextrose, and sodium chloride at these concentrations do not alter fertility based on animal studies and clinical experience. |
■ FDA Black Box Warning
No FDA boxed warning for this specific combination product. However, potassium chloride products in general carry a warning about rapid infusion causing hyperkalemia and cardiac arrest.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaHyperglycemia with comaHypernatremiaHypersensitivity to any componentFluid overload (e.g., congestive heart failure)
| Precautions | Monitor serum potassium, glucose, and electrolytes regularly, Use caution in renal impairment, heart failure, or conditions predisposing to hyperkalemia, Risk of hyperkalemia if administered too rapidly or in patients with impaired renal function, Avoid in patients with elevated potassium levels, Use with caution in patients receiving potassium-sparing diuretics or ACE inhibitors |
| Food/Dietary | No direct food interactions, but dietary potassium intake should be considered in patients on this therapy. Avoid potassium-rich foods (e.g., bananas, oranges, tomatoes) if serum potassium is elevated. |
| Clinical Pearls | This solution provides potassium, dextrose, and sodium chloride for maintenance or replacement therapy. Monitor serum potassium and glucose levels closely, especially in patients with renal impairment or diabetes. Avoid in patients with hyperkalemia, severe metabolic acidosis, or hyperglycemia. Rate of administration should be adjusted based on patient's fluid and electrolyte status. Incompatible with amphotericin B, diazepam, and phenytoin. |
| Patient Advice | This medication is given intravenously to replenish fluids, sugar, and electrolytes. · Report any symptoms like chest pain, irregular heartbeat, muscle weakness, or tingling sensations. · Inform your healthcare provider if you have kidney problems, diabetes, or heart conditions. · Do not adjust the infusion rate yourself; it is controlled by the medical team. · Tell your doctor about all other medications you are taking, especially diuretics or ACE inhibitors. |
Loading safety data…